Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2013

View Archived Issues

Lithium carbonate evaluated in phase II/III trial in Machado-Joseph disease

Serum ferritin levels predict response to chemotherapy in AML

Germline DICER1 gene mutations common in pleuropulmonary blastoma

FDA recommends additional trial of StemEx

Fibrocell Science and Intrexon expand strategic collaboration

Bayer completes acquisition of German company

Bioventus acquires rights to Pfizer's bone morphogenetic protein portfolio

FDA places clinical hold on sovaprevir

Insmed updates progress of Arikace programs

Alnylam reports phase II data for ALN-TTR02

Pharming and Shanghai Institute of Pharmaceutical Industry form strategic collaboration

SCRI and AstraZeneca form personalized medicine partnership

AmpliPhi BioSciences signs global agreement with U.S. Army

TransTech Pharma meets with FDA for TTP-488

Galapagos begins phase I trial of GLPG-1205

Vasopressin precursor levels assessed in Legionnaires' disease and other pneumonias

In vitro and in vivo anti-HIV activity of a novel HIV-1 splicing inhibitor

Benefit of MAO inhibitors in Parkinson's disease may be due to effects on CNP

Dr. Reddy's Laboratories patents new Trk-A inhibitors

Novel sodium channel blockers disclosed by Pfizer

Ariad obtains European approval for use of Iclusig in two leukemia indications

Novel renin inhibitors divulged by Sun Pharma Advanced Research

Small-molecule angiogenesis and proliferation inhibitor targets multiple cancer pathways

FDA grants orphan drug status to Tromplate and carbamazepine

FDA grants priority review for obinutuzumab BLA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...